Trevi Therapeutics (TRVI) Net Cash Flow (2018 - 2026)

Trevi Therapeutics' Net Cash Flow history runs 9 years deep, the most recent figure standing at $498000.0 for Q1 2026.

• In Q1 2026, Net Cash Flow rose 103.38% year-over-year to $498000.0; the TTM figure through Mar 2026 stood at $38000.0 (down 99.32% YoY), while the FY2025 annual figure was -$15.2 million, down 993.12% from the prior year.
• Net Cash Flow was $498000.0 for Q1 2026 at Trevi Therapeutics, up from -$38.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $97.7 million in Q2 2025 to a low of -$60.2 million in Q3 2025.
• Historically, Net Cash Flow has averaged $2.2 million across 5 years, with a median of $498000.0 in 2026.
• Biggest YoY gain for Net Cash Flow was 11619.34% in 2025; the steepest drop was 2048.49% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$54.0 million in 2022, then jumped by 111.91% to $6.4 million in 2023, then soared by 180.55% to $18.0 million in 2024, then slumped by 310.34% to -$38.0 million in 2025, then jumped by 101.31% to $498000.0 in 2026.
• The last three Net Cash Flow figures came in at $498000.0 (Q1 2026), -$38.0 million (Q4 2025), and -$60.2 million (Q3 2025), per Business Quant data.